CN116194483A - 使用抗cd73抗体的癌症治疗方法 - Google Patents
使用抗cd73抗体的癌症治疗方法 Download PDFInfo
- Publication number
- CN116194483A CN116194483A CN202180055645.3A CN202180055645A CN116194483A CN 116194483 A CN116194483 A CN 116194483A CN 202180055645 A CN202180055645 A CN 202180055645A CN 116194483 A CN116194483 A CN 116194483A
- Authority
- CN
- China
- Prior art keywords
- antibody
- ser
- protein
- val
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065085P | 2020-08-13 | 2020-08-13 | |
| US63/065,085 | 2020-08-13 | ||
| PCT/EP2021/072020 WO2022033978A2 (en) | 2020-08-13 | 2021-08-06 | Cancer treatment methods using anti-cd73 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116194483A true CN116194483A (zh) | 2023-05-30 |
Family
ID=77595505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180055645.3A Pending CN116194483A (zh) | 2020-08-13 | 2021-08-06 | 使用抗cd73抗体的癌症治疗方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240270865A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4196500A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023537115A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230050378A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116194483A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022033978A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220002959A (ko) | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9493563B2 (en) * | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| JP2017517499A (ja) * | 2014-04-25 | 2017-06-29 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| US20180030144A1 (en) * | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| US20200024357A1 (en) * | 2018-06-18 | 2020-01-23 | Innate Pharma | Compositions and methods for treating cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| CA2487932A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| WO2016055609A1 (en) * | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| EP3259288B1 (en) | 2015-02-20 | 2026-07-22 | Innate Pharma | Cd73 blockade |
| CA3045376C (en) | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| US20200172628A1 (en) * | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| WO2020041404A1 (en) * | 2018-08-23 | 2020-02-27 | Macrogenics, Inc. | Pd-l1-binding molecules and use of the same for the treatment of disease |
| KR20220002959A (ko) * | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
-
2021
- 2021-08-06 KR KR1020237007954A patent/KR20230050378A/ko not_active Withdrawn
- 2021-08-06 EP EP21763253.8A patent/EP4196500A2/en active Pending
- 2021-08-06 US US18/020,955 patent/US20240270865A1/en active Pending
- 2021-08-06 CN CN202180055645.3A patent/CN116194483A/zh active Pending
- 2021-08-06 JP JP2023509614A patent/JP2023537115A/ja not_active Ceased
- 2021-08-06 WO PCT/EP2021/072020 patent/WO2022033978A2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9493563B2 (en) * | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| JP2017517499A (ja) * | 2014-04-25 | 2017-06-29 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| US20180030144A1 (en) * | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| US20200024357A1 (en) * | 2018-06-18 | 2020-01-23 | Innate Pharma | Compositions and methods for treating cancer |
Non-Patent Citations (2)
| Title |
|---|
| AKIL HAMMAMI: "Targeting the adenosine pathway for cancer immunotherapy", SEMINARS IN IMMUNOLOGY, no. 42, 30 April 2019 (2019-04-30), pages 1 - 7 * |
| MARTIN TURCOTTE: "CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy", CANCER RESEARCH, vol. 77, no. 20, 15 October 2017 (2017-10-15), pages 1 - 12 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240270865A1 (en) | 2024-08-15 |
| KR20230050378A (ko) | 2023-04-14 |
| EP4196500A2 (en) | 2023-06-21 |
| WO2022033978A3 (en) | 2022-04-14 |
| JP2023537115A (ja) | 2023-08-30 |
| WO2022033978A2 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230099801A1 (en) | Restoration of t cell activity via the cd39/cd73 axis | |
| JP7530913B2 (ja) | Cd73遮断抗体 | |
| EP3535298B1 (en) | Antibodies to pd-1 and uses thereof | |
| CN109071666B (zh) | 人脊髓灰质炎病毒受体(pvr)特异性抗体 | |
| CN111372606B (zh) | 增强atp释放作用 | |
| JP7065935B2 (ja) | 抗ly6g6d抗体及び使用方法 | |
| JP2023036587A (ja) | 癌を処置するための組成物及び方法 | |
| KR20200130403A (ko) | 항-cd73 항체 및 그의 사용 방법 | |
| KR20160146747A (ko) | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 | |
| JP2020510435A (ja) | 抗gitr抗体およびその使用方法 | |
| US20240270865A1 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| CA3259402A1 (en) | BINDING MOLECULES FOR CANCER TREATMENT | |
| RU2819204C2 (ru) | Антитела, блокирующие cd73 | |
| HK40060535B (en) | Cd73 blocking antibodies | |
| HK40060535A (zh) | Cd73阻断抗体 | |
| HK40014070A (en) | Antibodies to pd-1 and uses thereof | |
| HK40014070B (en) | Antibodies to pd-1 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |